Online inquiry

IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12428MR)

This product GTTS-WQ12428MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IFNG gene. The antibody can be applied in Hemophagocytic lymphohistiocytosis (HLH) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000619.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3458
UniProt ID P01579
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12428MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3949MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ11672MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ4282MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BIIB-033
GTTS-WQ8432MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HSP90mab
GTTS-WQ13044MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ15046MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ13358MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PR-1498487
GTTS-WQ8596MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HuJ591-DOTA
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW